histone deacetylase inhibitor trichostatin A (TSA), an agent that also targets cancer cells and tumor vasculature  ydroxamic acid (HA)-based histone deacetylase (HDAC) inhibitors, with trichostatin A (TSA) as the reference compound, are potential antitumoral drugs and show promise in the creation of long-term primary cell cultures  e reported a novel potential anticancer strategy by using histone deacetylase (HDAC) inhibitor to enhance the action of endocrine therapy in ERΞ±-positive breast cancer cell.
The well-described HDAC inhibitor, trichostatin A (TSA.
